ArticleAntimicrobial agents and chemotherapy2012
Occidiofungin's chemical stability and in vitro potency against Candida species.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Ecological Diversity, Metabolic Versatility, and Biotechnological Applications ofAntibiotics (Basel, Switzerland) · 2025Review
- Development of an LC-MS/MS Method for Quantifying Occidiofungin in Rabbit Plasma.Journal of mass spectrometry : JMS · 2025Article
- The limitless endophytes: their role as antifungal agents against top priority pathogens.Microbial cell factories · 2024Review
- Intravaginal Gel for Sustained Delivery of Occidiofungin and Long-Lasting Antifungal Effects.Gels (Basel, Switzerland) · 2023Article
- Compilation of the Antimicrobial Compounds Produced byMolecules (Basel, Switzerland) · 2023Review
- Occidiofungin: Actin Binding as a Novel Mechanism of Action in an Antifungal Agent.Antibiotics (Basel, Switzerland) · 2022Review
- Underexplored bacteria as reservoirs of novel antimicrobial lipopeptides.Frontiers in chemistry · 2022Review
- Drug discovery through the isolation of natural products from Burkholderia.Expert opinion on drug discovery · 2021Review
- Formulation, Pharmacological Evaluation, and Efficacy Studies of Occidiofungin, a Novel Antifungal.Antimicrobial agents and chemotherapy · 2020Article
- Novel Antiparasitic Activity of the Antifungal Lead Occidiofungin.Antimicrobial agents and chemotherapy · 2020Article
- Article
- A Novel Actin Binding Drug withAntimicrobial agents and chemotherapy · 2019Article
- Nonribosomal peptides and polyketides of Burkholderia: new compounds potentially implicated in biocontrol and pharmaceuticals.Environmental science and pollution research international · 2018Review
- Modifying the Lantibiotic Mutacin 1140 for Increased Yield, Activity, and Stability.Applied and environmental microbiology · 2018Article
- Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2.Applied and environmental microbiology · 2018Article
- Burkholderia contaminans Colonization from Contaminated Liquid Docusate (Colace) in a Immunocompetent Adult with Legionnaire's Disease: Infection Control Implications and the Potential Role of Candida pellucosa.Journal of clinical medicine · 2016Article
- Comparative genome-wide analysis reveals that Burkholderia contaminans MS14 possesses multiple antimicrobial biosynthesis genes but not major genetic loci required for pathogenesis.MicrobiologyOpen · 2016Article
- The first reported case of Burkholderia contaminans in patients with cystic fibrosis in Ireland: from the Sargasso Sea to Irish Children.BMC pulmonary medicine · 2016Article
- Antifungal activity of Brevibacillus laterosporus JX-5 and characterization of its antifungal components.World journal of microbiology & biotechnology · 2015Article
- Draft Genome Sequence of Burkholderia pyrrocinia Lyc2, a Biological Control Strain That Can Suppress Multiple Plant Microbial Pathogens.Genome announcements · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Occidiofungin is a cyclic glyco-lipopeptide produced by Burkholderia contaminans. MICs against Candida species were between 0.5 and 2.0 μg/ml. Occidiofungin retains its in vitro potency in the presence of 5% and 50% human serum with a minimal lethal concentration (MLC) of 2 and 4 μg/ml, respectively. Time-kill and postantifungal effect (PAFE) experiments of occidiofungin against Candida albicans were performed. The results demonstrate that occidiofungin is fungicidal. Occidiofungin was also found to be a very stable molecule. It is resistant to extreme temperatures and pH and maintains its activity following exposure to gastric proteases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.